Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
Nobel prizes in 2026 will be declared during the first half of October, and there…
The Nobel Prize in Economics for 2026 has been conferred upon two American economists, Robert…
The World Bank has been in talks with 30-40 countries regarding possible assistance as a…
Jantar Mantar in the National Capital, New Delhi has been de-notified as a protest venue…
SEBI (ecurities and Exchange Board of India) has launched the Credit Risk-o-Meter on 7th of…
Sunil Bharti Mittal, the founder and chairman of Bharti Enterprises, is set to be conferred…